Pfizer said it expected to apply in November for US authorisation of its Covid-19 vaccine for children aged between six months and five-years-old as it races to expand eligibility for the jab.
The vaccine, developed in partnership with BioNTech, was the first to be authorised for use in children aged 12 and over, and Pfizer had already said it planned to apply for a green light from the US Food and Drug Administration for five-to-11-year-olds in early October.
On Tuesday, Pfizer offered the first glimpse of its intended timeline for authorisation of the jab in infants as young as six-months-old. Frank D’Amelio, chief financial officer, told an industry conference the company hoped to “go file” for this age group in November.
您已阅读29%（732字），剩余71%（1770字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。